INFORMS-Study in PPMS

I enjoy reading the comments on my posts – at this point, a big thank you to everyone who contributes here – and therefore a comment on my post “News from the AAN 2015 about PPMS”, caught my attention, which I would like to briefly address.Anonymous writes on May 21, 2015 at 2:56 pm: “So am I understanding correctly that I can stop the therapy with Gilenya after these new findings about Gilenya, as it doesn’t do anything anyway or just damages/weakens the immune system?” I would like to clarify: The INFORMS study on the treatment of primary progressive MS (PPMS) with Gilenya (Fingolimod), which I reported on in that post, was negative. Gilenya (Fingolimod) will therefore not receive a recommendation for approval for the treatment of PPMS. PPMS affects between 7 – 10% of patients with MS. For them, according to the study, Fingolimod offers no benefit. For patients with relapsing-remitting MS (RRMS – this is how about 80% of all MS diseases start), nothing has changed as a result of the results of the INFORMS study, they should not be confused by the study results.